Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors

Author:

Krishnamurthy Sateesh1,Traore Soumba1,Cooney Ashley L1,Brommel Christian M12,Kulhankova Katarina1,Sinn Patrick L12,Newby Gregory A345,Liu David R345,McCray Paul B12

Affiliation:

1. Department of Pediatrics, University of Iowa, Iowa City, IA, USA

2. Molecular Medicine Graduate Program, Pappajohn Biomedical Institute, University of Iowa, Iowa City, IA, USA

3. Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA, USA

4. Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA

5. Howard Hughes Medical Institute, Harvard University, Cambridge, MA, USA

Abstract

Abstract Mutations in the CFTR gene that lead to premature stop codons or splicing defects cause cystic fibrosis (CF) and are not amenable to treatment by small-molecule modulators. Here, we investigate the use of adenine base editor (ABE) ribonucleoproteins (RNPs) that convert A•T to G•C base pairs as a therapeutic strategy for three CF-causing mutations. Using ABE RNPs, we corrected in human airway epithelial cells premature stop codon mutations (R553X and W1282X) and a splice-site mutation (3849 + 10 kb C > T). Following ABE delivery, DNA sequencing revealed correction of these pathogenic mutations at efficiencies that reached 38–82% with minimal bystander edits or indels. This range of editing was sufficient to attain functional correction of CFTR-dependent anion channel activity in primary epithelial cells from CF patients and in a CF patient-derived cell line. These results demonstrate the utility of base editor RNPs to repair CFTR mutations that are not currently treatable with approved therapeutics.

Funder

National Institutes of Health

Center for Gene Therapy of Cystic Fibrosis

Cystic Fibrosis Foundation

Helen Hay Whitney

HHMI

Roy J. Carver Charitable Trust

Publisher

Oxford University Press (OUP)

Subject

Genetics

Reference90 articles.

1. VX-659-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles;Davies;N. Engl. J. Med.,2018

2. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles;Keating;N. Engl. J. Med.,2018

3. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation;Ramsey;N. Engl. J. Med.,2011

4. Making precision medicine personal for cystic fibrosis;Manfredi;Science,2019

5. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis;Aslam;Cochrane Database Syst. Rev.,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3